|
Market Closed -
Other stock markets
|
After hours 18:37:18 | |||
| 217.99 USD | -7.10% |
|
218.38 | +0.18% |
| 07-31 | Mizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating | MT |
| 07-21 | BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target | MT |
Company Valuation: Axsome Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,424 | 3,349 | 3,766 | 4,100 | 9,207 | 11,218 | - | - |
| Change | - | 135.22% | 12.44% | 8.87% | 124.55% | 21.83% | - | - |
| Enterprise Value (EV) 1 | 1,387 | 3,243 | 3,558 | 3,966 | 9,072 | 11,107 | 10,824 | 10,247 |
| Change | - | 133.87% | 9.72% | 11.46% | 128.76% | 22.43% | -2.55% | -5.33% |
| P/E | -10.9x | -16.8x | -15.1x | -14.1x | -49.6x | -106x | 39.3x | 16.3x |
| PBR | 90.9x | 30.6x | 19.7x | 72.2x | 105x | 11,546x | 37.9x | 13.3x |
| PEG | - | -0.5x | -1x | -1x | 1.3x | 2.4x | -0x | 0x |
| Capitalization / Revenue | - | 66.9x | 13.9x | 10.6x | 14.4x | 11.5x | 7.03x | 4.96x |
| EV / Revenue | - | 64.8x | 13.1x | 10.3x | 14.2x | 11.3x | 6.78x | 4.53x |
| EV / EBITDA | -11.1x | -18.5x | -15.8x | -14.5x | -56.7x | -81.2x | 45.8x | 19.3x |
| EV / EBIT | -11.1x | -18x | -15.3x | -14.1x | -54.4x | -113x | 32.4x | 12.2x |
| EV / FCF | -12.8x | -27.7x | -24.4x | -30.8x | -96.6x | -317x | 27.9x | 14.4x |
| FCF Yield | -7.83% | -3.61% | -4.09% | -3.24% | -1.03% | -0.32% | 3.58% | 6.94% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.47 | -4.6 | -5.27 | -5.99 | -3.68 | -2.061 | 5.553 | 13.4 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 50.04 | 270.6 | 385.7 | 638.5 | 978.9 | 1,596 | 2,260 |
| EBITDA 1 | -124.6 | -175.4 | -225 | -273.6 | -159.9 | -136.7 | 236.2 | 531.7 |
| EBIT 1 | -124.7 | -179.8 | -231.8 | -280.6 | -166.8 | -98.1 | 333.6 | 843.3 |
| Net income 1 | -130.4 | -187.1 | -239.2 | -287.2 | -183.2 | -107.3 | 309.1 | 763.2 |
| Net Debt 1 | -37.38 | -106.6 | -208.1 | -134.6 | -135.2 | -110.7 | -393.8 | -970.8 |
| Reference price 2 | 37.78 | 77.13 | 79.59 | 84.61 | 182.64 | 217.99 | 217.99 | 217.99 |
| Nbr of stocks (in thousands) | 37,692 | 43,426 | 47,320 | 48,462 | 50,413 | 51,460 | - | - |
| Announcement Date | 3/1/22 | 2/27/23 | 2/20/24 | 2/18/25 | 2/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -113.82x | 12.22x | -87.5x | -.--% | 12.07B | |
| 16.67x | 4.1x | 9.59x | 0.52% | 75.12B | |
| 23.58x | 4.83x | 14.44x | 0.67% | 47.63B | |
| 37.18x | 12.72x | 24.2x | -.--% | 49.48B | |
| -48.03x | 3.36x | 9.93x | 3.18% | 42.95B | |
| 38.13x | 3.45x | 12x | -.--% | 30.72B | |
| 56.6x | 3.48x | 26.97x | -.--% | 24.93B | |
| -6.68x | 9.36x | -5.75x | -.--% | 22.98B | |
| 63.54x | 6.22x | 42.81x | -.--% | 19.56B | |
| 24.79x | 5.31x | 13.83x | -.--% | 17.19B | |
| Average | 9.20x | 6.50x | 6.05x | 0.44% | 34.26B | |
| Weighted average by Cap. | 14.23x | 6.07x | 11.56x | 0.61% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AXSM Stock
- Valuation Axsome Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
